Proteins and Peptides

12 May 2019 NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA
07 May 2019 European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
07 May 2019 Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
30 Apr 2019 BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
29 Apr 2019 Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
28 Apr 2019 Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union
28 Apr 2019 Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A
26 Apr 2019 Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes
24 Apr 2019 Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate
23 Apr 2019 Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid
12 Apr 2019 89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
09 Apr 2019 PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
08 Apr 2019 Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
03 Apr 2019 Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
03 Apr 2019 Sandoz resubmits biosimilar pegfilgrastim application to US FDA
30 Mar 2019 Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
26 Mar 2019 Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
26 Mar 2019 Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation
26 Mar 2019 Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
26 Mar 2019 Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
24 Mar 2019 Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
21 Mar 2019 OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
21 Mar 2019 AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.
20 Mar 2019 Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia
20 Mar 2019 Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top